MA39085B1 - Combination of cineol and amoxicillin for use in the treatment of a bacterial infection - Google Patents
Combination of cineol and amoxicillin for use in the treatment of a bacterial infectionInfo
- Publication number
- MA39085B1 MA39085B1 MA39085A MA39085A MA39085B1 MA 39085 B1 MA39085 B1 MA 39085B1 MA 39085 A MA39085 A MA 39085A MA 39085 A MA39085 A MA 39085A MA 39085 B1 MA39085 B1 MA 39085B1
- Authority
- MA
- Morocco
- Prior art keywords
- combination
- cineol
- amoxicillin
- treatment
- bacterial infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une combinaison de cinéol et d' amoxicilline pour une utilisation dans le traitement d'une infection bactérienne chez un sujet. La présente combinaison peut en outre comprendre un inhibiteur de p-lactamases, de préférence de l'acide clavulanique. La combinaison selon l'invention permet en particulier de lutter contre les infections causées par des bactéries résistantes aux antibiotiques, de préférence aux antibiotiques de la famille des p-lactamines.The present invention relates to a combination of cineol and amoxicillin for use in the treatment of a bacterial infection in a subject. The present combination may further comprise an β-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to fight against infections caused by bacteria resistant to antibiotics, preferably antibiotics of the β-lactam family.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MA39085A MA39085B1 (en) | 2016-06-02 | 2016-06-02 | Combination of cineol and amoxicillin for use in the treatment of a bacterial infection |
PCT/MA2017/000014 WO2017209588A2 (en) | 2016-06-02 | 2017-06-02 | Pharmaceutical formulation comprising cineol and amoxicillin |
US16/306,262 US11872216B2 (en) | 2016-06-02 | 2017-06-02 | Pharmaceutical formulation comprising cineole and amoxicillin |
EA201892808A EA201892808A1 (en) | 2016-06-02 | 2017-06-02 | PHARMACEUTICAL PREPARATION, INCLUDING CINEOL AND AMOXICILLIN |
BR112018074913-3A BR112018074913B1 (en) | 2016-06-02 | 2017-06-02 | PHARMACEUTICAL FORMULATION OF CINEOL AND AMOXICILLIN |
EP17743405.7A EP3463479A2 (en) | 2016-06-02 | 2017-06-02 | Pharmaceutical formulation comprising cineol and amoxicillin |
CA3026323A CA3026323A1 (en) | 2016-06-02 | 2017-06-02 | Pharmaceutical formulation comprising cineol and amoxicillin |
JP2019515760A JP7033586B2 (en) | 2016-06-02 | 2017-06-02 | Pharmaceutical product containing cineole and amoxicillin |
CN201780041549.7A CN109562182A (en) | 2016-06-02 | 2017-06-02 | Pharmaceutical preparation comprising cineole and Amoxicillin |
MA044286A MA44286A (en) | 2016-06-02 | 2017-06-02 | PHARMACEUTICAL FORMULATION OF CINEOL AND AMOXICILLIN |
US18/408,636 US20240148702A1 (en) | 2016-06-02 | 2024-01-10 | Pharmaceutical formulation comprising cineole and amoxicillin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MA39085A MA39085B1 (en) | 2016-06-02 | 2016-06-02 | Combination of cineol and amoxicillin for use in the treatment of a bacterial infection |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39085A1 MA39085A1 (en) | 2017-12-29 |
MA39085B1 true MA39085B1 (en) | 2018-06-29 |
Family
ID=61167677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39085A MA39085B1 (en) | 2016-06-02 | 2016-06-02 | Combination of cineol and amoxicillin for use in the treatment of a bacterial infection |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA201892808A1 (en) |
MA (1) | MA39085B1 (en) |
-
2016
- 2016-06-02 MA MA39085A patent/MA39085B1/en unknown
-
2017
- 2017-06-02 EA EA201892808A patent/EA201892808A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201892808A1 (en) | 2019-05-31 |
MA39085A1 (en) | 2017-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991523A1 (en) | COMBINED THERAPY BY AMIDINE-SUBSTITUTED BETA-LACTAMIC COMPOUNDS AND INHIBITORS OF BETA-LACTAMASE IN INFECTIONS CAUSED BY BACTERIAL STRAINS RESISTANT TO ANTIBIOTICS | |
EP4282489A3 (en) | Treatment of clostridium difficile infection | |
MA37383A1 (en) | Heterobicyclic compound as inhibitors of beta lactamase | |
PH12019500558A1 (en) | Beta-lactamase inhibitor compounds | |
BR112013032770A2 (en) | pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor | |
MA32025B1 (en) | Beta-lactamase inhibitors | |
BR112013032711A2 (en) | pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
BR112017010132A2 (en) | combination therapy for treatment of resistant bacterial infections | |
FR3029790B1 (en) | CHITOSAN HYDROGEL MICROBELL | |
EP3860619A4 (en) | Compositions and methods for the treatment of pathogenic infections in plants | |
RU2015102562A (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING MASTITIS | |
WO2021022163A3 (en) | Compounds and uses thereof | |
MA53085B1 (en) | Substituted thiophenecarboxamides and analogs as antibacterial agents | |
ZA202006612B (en) | Antibacterial compounds | |
WO2017218922A8 (en) | Compositions and methods for the treatment of bacterial infections | |
EP4268897A3 (en) | Minocycline compounds for biodefense | |
EP4272831A3 (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
MX2022006109A (en) | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors. | |
WO2014165126A3 (en) | Derivatized 3-styryl-cephalosporins | |
NZ706734A (en) | Pharmaceutical compositions useful for the treatment or control of bacterial infections | |
MX2019011908A (en) | Anti-bacterial peptide macrocycles and use thereof. | |
MX2019007361A (en) | Oral care compositions. | |
PH12019500331A1 (en) | Beta-lactamase inhibitors | |
WO2020014501A8 (en) | Compositions and methods for the treatment of bacterial infections | |
MA39085A1 (en) | Combination of cineol and amoxicillin for use in the treatment of a bacterial infection |